The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
Characteristics
Recombinant Humanized IgG1 Monoclonal Antibody.
Purification
Protein A affinity column
Purity
> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterility
0.2 μm filtered
Endotoxin Level
< 1 EU per 1 mg of the protein by the LAL method.
Immunogen
The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
Isotype
IgG1 kappa
Application Notes
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Preservative
Without preservative
Handling Advice
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Storage
-20 °C
Storage Comment
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Expiry Date
12 months
Target
RSV (Palivizumab Biosimilar)
Target Type
Biosimilar
Background
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.